JP2013501038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501038A5 JP2013501038A5 JP2012523352A JP2012523352A JP2013501038A5 JP 2013501038 A5 JP2013501038 A5 JP 2013501038A5 JP 2012523352 A JP2012523352 A JP 2012523352A JP 2012523352 A JP2012523352 A JP 2012523352A JP 2013501038 A5 JP2013501038 A5 JP 2013501038A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- vector
- nucleic acid
- hbv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 38
- 102000039446 nucleic acids Human genes 0.000 claims 32
- 108020004707 nucleic acids Proteins 0.000 claims 32
- 150000007523 nucleic acids Chemical class 0.000 claims 32
- 239000013598 vector Substances 0.000 claims 30
- 230000002163 immunogen Effects 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 27
- 125000003729 nucleotide group Chemical group 0.000 claims 25
- 239000002773 nucleotide Substances 0.000 claims 24
- 208000015181 infectious disease Diseases 0.000 claims 16
- 230000002458 infectious effect Effects 0.000 claims 13
- 239000002245 particle Substances 0.000 claims 12
- 125000000539 amino acid group Chemical group 0.000 claims 11
- 238000006467 substitution reaction Methods 0.000 claims 11
- 241000700605 Viruses Species 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 230000003612 virological effect Effects 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 5
- 239000013603 viral vector Substances 0.000 claims 5
- 108700024845 Hepatitis B virus P Proteins 0.000 claims 4
- 102100034349 Integrase Human genes 0.000 claims 4
- 102100034353 Integrase Human genes 0.000 claims 4
- 108010078428 env Gene Products Proteins 0.000 claims 4
- 241000700721 Hepatitis B virus Species 0.000 claims 3
- 206010037742 Rabies Diseases 0.000 claims 3
- 230000002950 deficient Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000011301 standard therapy Methods 0.000 claims 2
- -1 terbivudine Chemical compound 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- 241000178270 Canarypox virus Species 0.000 claims 1
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101710091045 Envelope protein Proteins 0.000 claims 1
- 241000700662 Fowlpox virus Species 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 101710188315 Protein X Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229960001997 adefovir Drugs 0.000 claims 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960000980 entecavir Drugs 0.000 claims 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305742 | 2009-08-07 | ||
| EP09305742.0 | 2009-08-07 | ||
| PCT/EP2010/061492 WO2011015656A2 (en) | 2009-08-07 | 2010-08-06 | Composition for treating hbv infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015232256A Division JP6246778B2 (ja) | 2009-08-07 | 2015-11-27 | Ｈｂｖ感染を治療するための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013501038A JP2013501038A (ja) | 2013-01-10 |
| JP2013501038A5 true JP2013501038A5 (enExample) | 2013-09-12 |
| JP5897464B2 JP5897464B2 (ja) | 2016-03-30 |
Family
ID=43087099
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523352A Expired - Fee Related JP5897464B2 (ja) | 2009-08-07 | 2010-08-06 | Ｈｂｖ感染を治療するための組成物 |
| JP2015232256A Expired - Fee Related JP6246778B2 (ja) | 2009-08-07 | 2015-11-27 | Ｈｂｖ感染を治療するための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015232256A Expired - Fee Related JP6246778B2 (ja) | 2009-08-07 | 2015-11-27 | Ｈｂｖ感染を治療するための組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9393299B2 (enExample) |
| EP (1) | EP2461826A2 (enExample) |
| JP (2) | JP5897464B2 (enExample) |
| KR (1) | KR20120052352A (enExample) |
| CN (2) | CN102573903B (enExample) |
| BR (1) | BR112012002628B1 (enExample) |
| CA (1) | CA2770075C (enExample) |
| IL (1) | IL217926A (enExample) |
| MX (1) | MX2012001592A (enExample) |
| NZ (1) | NZ598000A (enExample) |
| RU (1) | RU2555346C2 (enExample) |
| SG (1) | SG178254A1 (enExample) |
| TW (1) | TWI555531B (enExample) |
| WO (1) | WO2011015656A2 (enExample) |
| ZA (1) | ZA201200899B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9393299B2 (en) * | 2009-08-07 | 2016-07-19 | Transgene S.A. | Composition for treating HBV infection |
| JP2014523878A (ja) * | 2011-06-14 | 2014-09-18 | グローブイミューン，インコーポレイテッド | Ｄ型肝炎ウイルス感染の治療又は予防のための酵母ベースの組成物及び方法 |
| TWI623618B (zh) * | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| US9946495B2 (en) * | 2013-04-25 | 2018-04-17 | Microsoft Technology Licensing, Llc | Dirty data management for hybrid drives |
| WO2016020538A1 (en) * | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| CN107530410B (zh) | 2015-03-18 | 2021-11-09 | 欧姆尼赛特有限公司 | 包含经修饰的α病毒表面糖蛋白与肿瘤相关抗原的融合蛋白及其方法 |
| CN106148404B (zh) * | 2015-03-25 | 2020-01-24 | 复旦大学 | 一种人乙型肝炎病毒重组载体及其应用 |
| JP6566368B2 (ja) * | 2015-04-16 | 2019-08-28 | 国立研究開発法人産業技術総合研究所 | Ｂ型肝炎ウイルス分泌阻害剤 |
| CN108779472B (zh) * | 2015-11-04 | 2022-09-09 | 霍欧奇帕生物科技有限公司 | 针对乙型肝炎病毒的疫苗 |
| US11266727B2 (en) | 2015-11-12 | 2022-03-08 | Hookipa Biotech Gmbh | Arenavirus particles as cancer vaccines |
| US9963751B2 (en) | 2015-11-24 | 2018-05-08 | The Penn State Research Foundation | Compositions and methods for identifying agents to reduce hepatitis B virus covalently closed circular DNA |
| PT3402888T (pt) * | 2016-01-12 | 2020-12-04 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Meios e métodos para tratamento do hbv |
| AU2017249424B2 (en) | 2016-04-13 | 2023-08-24 | Janssen Pharmaceuticals, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| CN109641044A (zh) * | 2016-05-30 | 2019-04-16 | 吉奥瓦科斯公司 | 用于产生对乙型肝炎病毒的免疫应答的组合物和方法 |
| AU2017286623A1 (en) * | 2016-06-15 | 2018-12-20 | Oxford University Innovation Limited | Dual overlapping adeno-associated viral vector system for expressing ABC4A |
| EP3276006A1 (en) * | 2016-07-27 | 2018-01-31 | Theravectys | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| US11364310B2 (en) | 2016-10-17 | 2022-06-21 | Janssen Pharmaceuticals, Inc. | Recombinant virus replicon systems and uses thereof |
| WO2018106615A2 (en) | 2016-12-05 | 2018-06-14 | Synthetic Genomics, Inc. | Compositions and methods for enhancing gene expression |
| GB201705765D0 (en) * | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
| EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| EP3624845A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| GB201721069D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
| BR112020012273A2 (pt) * | 2017-12-19 | 2020-11-24 | Janssen Sciences Ireland Unlimited Company | métodos e composições para induzir uma resposta imune contra o vírus da hepatite b (hbv) |
| EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| KR20200101388A (ko) * | 2017-12-19 | 2020-08-27 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스 (hbv) 백신의 전달을 위한 방법 및 장치 |
| MX2020007675A (es) | 2018-01-19 | 2020-09-14 | Janssen Pharmaceuticals Inc | Induccion y mejora de respuestas inmunes utilizando sistemas de replicon recombinante. |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| KR102234027B1 (ko) * | 2018-05-09 | 2021-03-31 | 서울대학교산학협력단 | B형 간염 바이러스 유래 폴리펩티드 및 이의 항바이러스 용도 |
| CA3115480A1 (en) | 2018-10-08 | 2020-04-16 | Janssen Pharmaceuticals, Inc. | Alphavirus-based replicons for administration of biotherapeutics |
| CA3143679A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| KR20220041080A (ko) * | 2019-06-18 | 2022-03-31 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합 |
| CN114729010B (zh) | 2019-08-29 | 2025-02-28 | 维尔生物科技有限公司 | 乙型肝炎病毒疫苗 |
| JP7398556B2 (ja) * | 2019-09-30 | 2023-12-14 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖワクチン及びｈｂｖを治療する方法 |
| CN115003685A (zh) | 2019-12-07 | 2022-09-02 | Isa制药有限公司 | 乙型肝炎病毒相关疾病的治疗 |
| US20230287086A1 (en) * | 2020-07-17 | 2023-09-14 | Yang Sheng Tang Company, Ltd. | Cell-penetrating peptide and use thereof |
| CN114107377A (zh) * | 2020-08-31 | 2022-03-01 | 复旦大学附属华山医院 | 一种乙肝病毒载体及其应用 |
| WO2024223299A2 (en) | 2023-04-26 | 2024-10-31 | Isa Pharmaceuticals B.V. | Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor |
| WO2025226656A1 (en) * | 2024-04-23 | 2025-10-30 | Modernatx, Inc. | Hepatitis b virus mrna vaccines |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| FR2583429B1 (fr) | 1985-06-18 | 1989-11-03 | Transgene Sa | Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u |
| FR2650838A1 (fr) | 1989-08-09 | 1991-02-15 | Transgene Sa | Vecteurs d'expression du facteur ix dans une cellule eucaryote superieure, procede de preparation de facteur ix par des animaux transgeniques et facteur ix obtenu |
| NZ235315A (en) * | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
| EP0491077A1 (en) | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | A composition used as a therapeutic agent against chronic viral hepatic diseases |
| AU687725B2 (en) | 1991-08-26 | 1998-03-05 | Epimmune, Inc. | HLA-restricted hepatitis B virus CTL epitopes |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| ES2204912T3 (es) | 1993-02-26 | 2004-05-01 | The Scripps Research Institute | Peptidos que inducen respuestas de linfoccitos t citotoxicos contra el virus de la hepatitis b. |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| CA2164088C (en) * | 1993-06-07 | 2005-06-14 | Gary J. Nabel | Plasmids suitable for gene therapy |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| US5994128A (en) | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| CA2224477A1 (en) | 1995-06-20 | 1997-01-09 | Margherita Melegari | Inhibition of hepatitis b replication |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| SK181098A3 (en) | 1996-07-01 | 1999-07-12 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
| US5981274A (en) * | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| US6194191B1 (en) | 1996-11-20 | 2001-02-27 | Introgen Therapeutics, Inc. | Method for the production and purification of adenoviral vectors |
| WO1998026048A1 (en) | 1996-12-13 | 1998-06-18 | Schering Corporation | Methods for purifying viruses |
| EP0988053A1 (en) | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| US6596501B2 (en) * | 1998-02-23 | 2003-07-22 | Fred Hutchinson Cancer Research Center | Method of diagnosing autoimmune disease |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| JP3864610B2 (ja) | 1998-05-21 | 2007-01-10 | 旭硝子株式会社 | 水分散型撥水撥油剤組成物およびその製造方法 |
| BR9915942A (pt) | 1998-12-04 | 2001-08-21 | Biogen Inc | Patìculas de antìgeno de núcleo de hbv com componentes imunogênicos múltiplos ligados através de ligantes de peptìdeo |
| FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| JP2003523169A (ja) | 1998-12-31 | 2003-08-05 | アバンテイス・フアルマ・エス・アー | ウイルス粒子の分離法 |
| CA2364934C (fr) | 1999-02-22 | 2011-10-18 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| CA2372655C (en) | 1999-05-17 | 2011-11-15 | Crucell Holland B.V. | Recombinant adenovirus having low pre-existing neutralizing activity |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| FR2803599B1 (fr) * | 2000-01-06 | 2004-11-19 | Inst Nat Sante Rech Med | Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications |
| CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| EP1278542A2 (en) * | 2000-05-05 | 2003-01-29 | Cytos Biotechnology AG | Molecular antigen arrays and vaccines |
| US6858590B2 (en) * | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| EP1390398A2 (en) | 2001-05-30 | 2004-02-25 | Transgene S.A. | Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
| WO2003066841A1 (en) * | 2002-02-07 | 2003-08-14 | Melbourne Health | Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
| US7351413B2 (en) * | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
| PL208588B1 (pl) | 2002-04-25 | 2011-05-31 | Crucell Holland Bv | Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa |
| WO2004083418A1 (en) | 2003-03-17 | 2004-09-30 | Merck & Co., Inc. | Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby |
| CN1759177A (zh) | 2003-03-28 | 2006-04-12 | 麦克公司 | 腺病毒血清型34载体,核酸及其由此产生的病毒 |
| FR2855758B1 (fr) | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
| US7695960B2 (en) * | 2003-06-05 | 2010-04-13 | Transgene S.A. | Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use |
| US7485312B2 (en) | 2003-06-20 | 2009-02-03 | Dade Behring Marburg Gmbh | Surface protein (HBsAg) variant of the hepatitis B virus |
| JP2007530004A (ja) | 2003-07-18 | 2007-11-01 | オニックス ファーマシューティカルズ，インコーポレイティド | 疾患を処置するためのサブグループｂアデノウイルスベクター |
| ATE497974T1 (de) | 2003-07-21 | 2011-02-15 | Transgene Sa | Multifunktionelle cytokine |
| US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| DE10339927A1 (de) * | 2003-08-29 | 2005-03-24 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen |
| EP1692278B1 (en) * | 2003-10-21 | 2013-07-03 | Melbourne Health | Hbv variants detection and application |
| GB0328753D0 (en) | 2003-12-11 | 2004-01-14 | Royal Veterinary College The | Hepatitis B vaccines |
| US8470591B2 (en) | 2004-11-08 | 2013-06-25 | Transgene S.A. | Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal |
| EP1764369A1 (de) * | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
| GB0522578D0 (en) | 2005-11-04 | 2005-12-14 | King S College London | Ribozymal nucleic acid |
| CN101400366B (zh) * | 2006-03-09 | 2012-12-12 | 特兰斯吉恩股份有限公司 | 丙型肝炎病毒非结构性融合蛋白 |
| EP2029169A2 (en) * | 2006-06-20 | 2009-03-04 | Transgene S.A. | Recombinant viral vaccine |
| WO2008020656A1 (en) * | 2006-08-14 | 2008-02-21 | Postech Foundation | A dna vaccine for curing chronic hepatitis b and a method of preparing same |
| CN101688223B (zh) * | 2007-05-15 | 2013-07-31 | 特兰斯吉恩股份有限公司 | 用于多基因表达的载体 |
| CN102015753A (zh) * | 2008-01-25 | 2011-04-13 | 海德堡吕布莱希特-卡尔斯大学 | 乙肝病毒(HBV)的疏水性修饰的preS-衍生肽及其作为载体将化合物特异性递送到肝脏的用途 |
| US10076570B2 (en) * | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
| US9393299B2 (en) * | 2009-08-07 | 2016-07-19 | Transgene S.A. | Composition for treating HBV infection |
-
2010
- 2010-08-06 US US13/388,826 patent/US9393299B2/en not_active Expired - Fee Related
- 2010-08-06 SG SG2012007845A patent/SG178254A1/en unknown
- 2010-08-06 BR BR112012002628-3A patent/BR112012002628B1/pt not_active IP Right Cessation
- 2010-08-06 EP EP10737945A patent/EP2461826A2/en not_active Ceased
- 2010-08-06 KR KR1020127005033A patent/KR20120052352A/ko not_active Ceased
- 2010-08-06 CN CN201080042650.2A patent/CN102573903B/zh active Active
- 2010-08-06 CN CN201510884240.7A patent/CN105535960B/zh active Active
- 2010-08-06 MX MX2012001592A patent/MX2012001592A/es active IP Right Grant
- 2010-08-06 WO PCT/EP2010/061492 patent/WO2011015656A2/en not_active Ceased
- 2010-08-06 NZ NZ598000A patent/NZ598000A/xx not_active IP Right Cessation
- 2010-08-06 CA CA2770075A patent/CA2770075C/en active Active
- 2010-08-06 TW TW099126293A patent/TWI555531B/zh active
- 2010-08-06 JP JP2012523352A patent/JP5897464B2/ja not_active Expired - Fee Related
- 2010-08-06 RU RU2012107671/15A patent/RU2555346C2/ru active
-
2012
- 2012-02-02 IL IL217926A patent/IL217926A/en active IP Right Grant
- 2012-02-07 ZA ZA2012/00899A patent/ZA201200899B/en unknown
-
2015
- 2015-11-27 JP JP2015232256A patent/JP6246778B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-06 US US15/203,046 patent/US20170072047A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501038A5 (enExample) | ||
| RU2012107671A (ru) | Композиция для лечения инфекции вирусом гепатита в | |
| US20220396810A1 (en) | Vaccines and uses thereof to induce an immune response to sars-cov2 | |
| JP2014527404A5 (enExample) | ||
| US8435535B2 (en) | Fusion proteins of HIV regulatory/accessory proteins | |
| RU2014104360A (ru) | Мутантные полимеразы вируса гепатита в | |
| JP2008505985A5 (enExample) | ||
| JP2008529558A5 (enExample) | ||
| JP2015509707A5 (enExample) | ||
| RU2014135053A (ru) | Иммуногены для вакцинации против вич | |
| WO2006037038B1 (en) | Optimized vaccines to provide protection against ebola and other viruses | |
| JP2004501646A5 (enExample) | ||
| CN111741766A (zh) | 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物 | |
| US8765143B2 (en) | Fusion proteins and use thereof for preparing hepatitis C vaccines | |
| JP2018533908A5 (enExample) | ||
| JP2012501351A5 (enExample) | ||
| HK40074915B (zh) | 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用 | |
| CN119264229A (zh) | 基于SARS-CoV-2的不同奥密克戎变异型的S蛋白的疫苗和组合物 | |
| HK1111704A (en) | Fusion protein of hiv regulatory/accessory proteins | |
| HK1076822B (en) | Fusion protein of hiv regulatory/accessory proteins | |
| HK1104307A (en) | Fusion protein of hiv regulatory/accessory proteins |